DNTHEarnings•globenewswire•
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q2 Financial Results
Sentiment:Positive (70)
Summary
Phase 2 MaGic trial of claseprubart (DNTH103) in generalized Myasthenia Gravis (gMG) top-line results anticipated in September 2025; the first of three catalysts for the claseprubart neuromuscular franchise by YE’26
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on August 7, 2025 by globenewswire